To the Editor We read with great interest the results of the randomized clinical trial conducted by Cohen et al1 demonstrating the superiority of Roux-en-Y gastric bypass (RYGB) compared with optimal medical treatment regarding remission of albuminuria in patients with type 2 diabetes mellitus, obesity, and early-stage chronic kidney disease (CKD), primarily driven by the significant reduction in body mass index.1 Marginally significant improvement in glycemic control, along with no difference in blood pressure reduction, were shown for RYGB-treated patients compared with those randomized to pharmacologic intervention only, underlining the significance of induced weight loss regarding the assessed kidney end point.1
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Patoulias D, Papadopoulos C, Doumas M. The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. JAMA Surg. 2021;156(2):204. doi:10.1001/jamasurg.2020.5171
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.